Trial Profile
A retrospective study to evaluate efficacy of Nivolumab monotherapy in Japanese subjects with melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 Dec 2018 New trial record
- 17 Nov 2018 Results assessing the efficacy of nivolumab in Japanese patients with advanced melanoma, published in the British Journal of Dermatology.